ENDPOINTS

Lilly posts encouraging early-stage weight loss data on amylin candidate

Eli Lilly’s under-the-radar amylin analog allowed obese patients in a Phase 1 trial to lose up to 11.3% of their bodyweight. The drug appears to be more effective than similar offerings from companies in the ...

Jun 16, 2025 - 11:50
 0
Lilly posts encouraging early-stage weight loss data on amylin candidate
Eli Lilly’s under-the-radar amylin analog allowed obese patients in a Phase 1 trial to lose up to 11.3% of their bodyweight. The drug appears to be more effective than similar offerings from companies in the ...
Read More

Tags:

Previous Article

See Vera C. Rubin Observatory’s First Images Live with These Watch Parties

Next Article

One of Quest’s Most Popular Single-player Games Gets Multiplayer Mode as Social ...

Related Posts

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

FDA's oncology adcomm to review GSK's Blenrep relaunch ...

Jun 13, 2025  0

Investors pump $130M into protein degrader startup GlycoEra

Investors pump $130M into protein degrader startup Glyc...

May 27, 2025  0

Novo Nordisk ‘strongly’ urges US away from pharma tariffs

Novo Nordisk ‘strongly’ urges US away from pharma tariffs

May 28, 2025  0